Loki’s patented Myeloid Mediated Delivery (MMD) platform allows safe and specific delivery of a wide array of payloads to tumors and metastases, without affecting healthy tissue.
Key Benefits of our Approach
AWAKENING THE IMMUNE SYSTEM
Loki AWAKE technology activates and redirects pre-existing memory T cells created during childhood tetanus vaccination to generate a powerful and immediate immune response to solid tumors and metastases presenting the tetanus antigens.
SELECTIVE DELIVERY
In order to create a specific and selective immune response, we package the recall antigen payload into an attenuated bacterial vector.
This novel approach allows for the selective delivery of recall antigens to the immuno-suppressed tumor micro environment of solid tumors and metastases.
ROBUST RESPONSE
Once in the tumor micro environment, the attenuated bacteria selectively infects the tumor and delivers the recall antigen payload to the tumor cells, which then display it on their cell surface.
The recall antigens are then recognized by the immune system creating a strong memory T-cell mediated response, killing the tumor and metastases.
REPEAT DOSING POTENTIAL
Our approach has shown promise for repeat courses of therapy, avoiding some of the immunological and toxicity risks of previous approaches.
